Heidi Crayton
Georgetown University
5 Papers
1 Citations
Heidi Crayton is an academic researcher from Georgetown University. The author has contributed to research in topics: Medicine & Sexual dysfunction. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Managing the symptoms of multiple sclerosis: a multimodal approach.
Heidi Crayton,Howard Rossman +1 more
TL;DR: Careful clinical monitoring and individualization of pharmacologic and nonpharmacologic therapies are recommended to manage the symptoms of MS, with the goals of improving or maintaining function and preserving the patient's quality of life.
172
A multimodal approach to managing the symptoms of multiple sclerosis.
TL;DR: The symptom management model that provides optimal results for patients with MS is a multimodal approach using effective communication, patient education, physical modalities and activities, occupational and other therapies, and pharmacologic interventions.
133
•Journal Article
Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS (P6.167)
Heidi Crayton,Brian Steingo,DeRen Huang,Xiangyi Meng,Lesley Schofield,Kristen Johnson,Nadia Tenenbaum +6 more
TL;DR: The advantages of fingolimod over iDMTs in patient retention and treatment satisfaction support use of finglimod in early RRMS in the real world.
1
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
John F. Foley,Gilles Defer,Lana Zhovtis Ryerson,Jeffrey A. Cohen,Douglas L. Arnold,Helmut Butzkueven,Gary Cutter,Gavin Giovannoni,Joep Killestein,Heinz Wiendl,K. Smirnakis,Sha Xiao,George Kong,Robert Kuhelj,M. Campbell,A Van der Walt,Christopher M. Dwyer,Katherine Buzzard,Judith M. Spies,John Parratt,Vincent Van Pesch,Barbara Willekens,Gaetano Perrotta,Emmanuel Bartholomé,Francois Grand'Maison,Francois Jacques,Paul S. Giacomini,Reza Vosoughi,Jean-Marc Girard,Jérôme De Seze,Christine Lebrun Frenay,Aurélie Ruet,David Laplaud,G Reifschneider,Bert Wagner,Sebastian Rauer,Refik Pul,Maria Seipelt,Achim Berthele,Luisa Klotz,B Kallmann,Friedemann Paul,Anat Achiron,Giacomo Lus,Diego Centonze,Francesco Patti,Luigi M.E. Grimaldi,Raymond Hupperts,S. T. F. M. Frequin,Jiske Fermont,S. Eichau Madueño,Ana Maria Torres,L. C. França,José Meca-Lallana,Luis Brieva Ruiz,Owen R Pearson,David Rog,Nikos Evangelou,Azza Ismail,Ellen S. Lathi,Edward Fox,Thomas Leist,Jacob A. Sloane,Gregory F. Wu,Bhupendra Khatri,Brian Steingo,Ben W. Thrower,Mark Gudesblatt,Jonathan Calkwood,D. Bandari,John R. Scagnelli,Christopher LaGanke,Derrick Robertson,Lucas Kipp,M. I. Belkin,Stanley Cohan,L. Goldstick,Ardith Courtney,Wendy Vargas,Andrew Sylvester,J. Srinivasan,Meena Kannan,Mary Ann Picone,J English,Salvatore Q Napoli,Roumen Balabanov,Islam Zaydan,Jacqueline A. Nicholas,Jeffrey B. Kaplan,Fred D. Lublin,Emily Riser,Tamara Miller,Enrique Alvarez,Sibyl Wray,Jeffrey N. Gross,Siddharama Pawate,Carrie M. Hersh,Lucas McCarthy,Heidi Crayton,Jennifer Graves +99 more
TL;DR: The safety and efficacy of natalizumab once every 6 weeks compared with once every 4 weeks in patients with relapsing-remitting multiple sclerosis was assessed and one case of asymptomatic progressive multifocal leukoencephalopathy (without clinical signs) was reported.
Comparing First-line Natalizumab and Ocrelizumab Use for the Treatment of Multiple Sclerosis: A Komodo Health Claims Database Study (P7-1.012)
Jeffrey Kaplan,Dana Beenstock,Martin Belkin,Heidi Crayton,Christopher Eckstein,Ruth Fredericks,Boyang Bian,Nicholas Belviso,Daphne Ni,Danette Rutledge +9 more